Leiomyosarcoma
Leiomyosarcoma is a rare type of cancer that originates in smooth muscle tissue, which can occur in various parts of the body. It can be classified as metastatic, where the cancer has spread, or non-metastatic, where it is localized.
We are comparing two treatments, Trabectedin and Gemcitabine, for patients with advanced leiomyosarcoma who have already received chemotherapy. The goal is to see which treatment works better in slowing down cancer growth and improving survival.
Health conditions and diseases that the clinical trial is designed to study and treat.
Leiomyosarcoma is a rare type of cancer that originates in smooth muscle tissue, which can occur in various parts of the body. It can be classified as metastatic, where the cancer has spread, or non-metastatic, where it is localized.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.